ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Stem Cell and Exosome Therapy in Pulmonary Hypertension.

ÌÇÐÄ´«Ã½

Stem Cell and Exosome Therapy in Pulmonary Hypertension. Korean circulation journal Oh, S., Jung, J., Ahn, K., Jang, A. Y., Byun, K., Yang, P. C., Chung, W. 2022; 52 (2): 110-122

Abstract

Pulmonary hypertension is a rare and progressive illness with a devastating prognosis. Promising ÌÇÐÄ´«Ã½ efforts have advanced the understanding and recognition of the pathobiology of pulmonary hypertension. Despite remarkable achievements in terms of improving the survival rate, reducing disease progression, and enhancing quality of life, pulmonary arterial hypertension (PAH) is not completely curable. Therefore, an effective treatment strategy is still needed. Recently, many studies of the underlying molecular mechanisms and technological developments have led to new approaches and paradigms for PAH treatment. Management based on stem cells and related paracrine effects, epigenetic drugs and gene therapies has yielded prospective results for PAH treatment in preclinical ÌÇÐÄ´«Ã½. Further trials are ongoing to optimize these important insights into clinical circumstances.

View details for

View details for